184 related articles for article (PubMed ID: 28400426)
1. A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.
Yang L; Taylor J; Eustace A; Irlam JJ; Denley H; Hoskin PJ; Alsner J; Buffa FM; Harris AL; Choudhury A; West CML
Clin Cancer Res; 2017 Aug; 23(16):4761-4768. PubMed ID: 28400426
[No Abstract] [Full Text] [Related]
2. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Eustace A; Mani N; Span PN; Irlam JJ; Taylor J; Betts GN; Denley H; Miller CJ; Homer JJ; Rojas AM; Hoskin PJ; Buffa FM; Harris AL; Kaanders JH; West CM
Clin Cancer Res; 2013 Sep; 19(17):4879-88. PubMed ID: 23820108
[TBL] [Abstract][Full Text] [Related]
3. A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.
Khan MT; Irlam-Jones JJ; Pereira RR; Lane B; Valentine HR; Aragaki K; Dyrskjøt L; McConkey DJ; Hoskin PJ; Choudhury A; West CML
Br J Cancer; 2021 Jul; 125(1):85-93. PubMed ID: 33846523
[TBL] [Abstract][Full Text] [Related]
4. Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
Eustace A; Irlam JJ; Taylor J; Denley H; Agrawal S; Choudhury A; Ryder D; Ord JJ; Harris AL; Rojas AM; Hoskin PJ; West CM
Radiother Oncol; 2013 Jul; 108(1):40-7. PubMed ID: 23773411
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
Song YP; Mistry H; Irlam J; Valentine H; Yang L; Lane B; West C; Choudhury A; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1407-1415. PubMed ID: 33689854
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.
Yang L; Roberts D; Takhar M; Erho N; Bibby BAS; Thiruthaneeswaran N; Bhandari V; Cheng WC; Haider S; McCorry AMB; McArt D; Jain S; Alshalalfa M; Ross A; Schaffer E; Den RB; Jeffrey Karnes R; Klein E; Hoskin PJ; Freedland SJ; Lamb AD; Neal DE; Buffa FM; Bristow RG; Boutros PC; Davicioni E; Choudhury A; West CML
EBioMedicine; 2018 May; 31():182-189. PubMed ID: 29729848
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ; Saunders MI; Dische S
Cancer; 1999 Oct; 86(7):1322-8. PubMed ID: 10506720
[TBL] [Abstract][Full Text] [Related]
8. Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer.
Hunter BA; Eustace A; Irlam JJ; Valentine HR; Denley H; Oguejiofor KK; Swindell R; Hoskin PJ; Choudhury A; West CM
Br J Cancer; 2014 Jul; 111(3):437-43. PubMed ID: 24937673
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
Hoskin PJ; Rojas AM; Bentzen SM; Saunders MI
J Clin Oncol; 2010 Nov; 28(33):4912-8. PubMed ID: 20956620
[TBL] [Abstract][Full Text] [Related]
10. Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.
Irlam-Jones JJ; Eustace A; Denley H; Choudhury A; Harris AL; Hoskin PJ; West CM
Br J Cancer; 2016 Aug; 115(5):571-8. PubMed ID: 27441495
[TBL] [Abstract][Full Text] [Related]
11. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.
Hoskin P; Rojas A; Saunders M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1425-31. PubMed ID: 19036531
[TBL] [Abstract][Full Text] [Related]
12. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
[TBL] [Abstract][Full Text] [Related]
13. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ; Rojas AM; Phillips H; Saunders MI
Cancer; 2005 Jun; 103(11):2287-97. PubMed ID: 15834926
[TBL] [Abstract][Full Text] [Related]
14. Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer.
Yin H; Zhang C; Gou X; He W; Gan D
Oncol Rep; 2020 Feb; 43(2):379-394. PubMed ID: 31894276
[TBL] [Abstract][Full Text] [Related]
15. Developing Tumor Radiosensitivity Signatures Using LncRNAs.
Khan MT; Yang L; More E; Irlam-Jones JJ; Valentine HR; Hoskin P; Choudhury A; West CML
Radiat Res; 2021 Apr; 195(4):324-333. PubMed ID: 33577642
[TBL] [Abstract][Full Text] [Related]
16. Low CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer.
Smith V; Mukherjee D; Tsakiroglou AM; Baker A; Mistry H; Choudhury A; Hoskin P; Illidge T; West CML
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612036
[TBL] [Abstract][Full Text] [Related]
17. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.
Riester M; Taylor JM; Feifer A; Koppie T; Rosenberg JE; Downey RJ; Bochner BH; Michor F
Clin Cancer Res; 2012 Mar; 18(5):1323-33. PubMed ID: 22228636
[TBL] [Abstract][Full Text] [Related]
18. Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer.
Mitra AP; Lam LL; Ghadessi M; Erho N; Vergara IA; Alshalalfa M; Buerki C; Haddad Z; Sierocinski T; Triche TJ; Skinner EC; Davicioni E; Daneshmand S; Black PC
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25344601
[TBL] [Abstract][Full Text] [Related]
19. Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting.
Anzela A; Min M; Knesl M; Buddle N; Azzopardi M; Hooshmand R; Barrett S; Notman A; Woolls H; Wilson J; Vignarajah DD
J Med Imaging Radiat Oncol; 2021 Oct; 65(6):768-777. PubMed ID: 34196122
[TBL] [Abstract][Full Text] [Related]
20. ARCON: a novel biology-based approach in radiotherapy.
Kaanders JH; Bussink J; van der Kogel AJ
Lancet Oncol; 2002 Dec; 3(12):728-37. PubMed ID: 12473514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
